His primary scientific interests are in Internal medicine, Pulmonary hypertension, Cardiology, Surgery and Respiratory disease. His research on Internal medicine frequently links to adjacent areas such as Endocrinology. His work carried out in the field of Pulmonary hypertension brings together such families of science as Hazard ratio, Survival rate, Hemodynamics, Vascular resistance and Interstitial lung disease.
His studies in Cardiology integrate themes in fields like Blood pressure and Intensive care. His work on Randomized controlled trial, Heart catheterization and Proportional hazards model as part of general Surgery research is frequently linked to Associated Pulmonary Arterial Hypertension, thereby connecting diverse disciplines of science. His Respiratory disease research is multidisciplinary, relying on both Cardiac index and Pneumonia.
His primary areas of study are Internal medicine, Pulmonary hypertension, Cardiology, Pathology and Hemodynamics. His Internal medicine study incorporates themes from Endocrinology and Surgery. His Pulmonary hypertension study combines topics from a wide range of disciplines, such as Respiratory disease, Lung, Immunology, Intensive care medicine and Hazard ratio.
His Intensive care medicine research incorporates themes from Clinical trial and Disease. His study on Vascular resistance, Heart failure, Pulmonary wedge pressure and Ventricular function is often connected to In patient as part of broader study in Cardiology. His Lung injury research is multidisciplinary, incorporating elements of Oxidative stress, Pharmacology and Vascular permeability.
The scientist’s investigation covers issues in Internal medicine, Pulmonary hypertension, Cardiology, Intensive care medicine and Biomarker. His Internal medicine study often links to related topics such as Gastroenterology. Paul M. Hassoun interconnects Disease severity and Hazard ratio in the investigation of issues within Gastroenterology.
Paul M. Hassoun has researched Pulmonary hypertension in several fields, including Afterload, Blood pressure, Magnetic resonance imaging, Fibrosis and Contractility. His study focuses on the intersection of Contractility and fields such as Supine position with connections in the field of Cardiac magnetic resonance imaging. His Cardiology study which covers Vascular disease that intersects with Omics and Right heart catheterization.
Paul M. Hassoun spends much of his time researching Internal medicine, Pulmonary hypertension, Cardiology, Intensive care medicine and MEDLINE. His work deals with themes such as Gastroenterology and Imaging biomarker, which intersect with Internal medicine. The concepts of his Pulmonary hypertension study are interwoven with issues in Biomarker, Heart failure, Magnetic resonance imaging, Fibrosis and In vivo.
His Fibrosis research incorporates elements of Inflammation, Immunology, Pulmonary artery banding and Brain natriuretic peptide. His Intensive care medicine research is multidisciplinary, incorporating elements of Pulmonary embolism and Ventricular function. His MEDLINE study integrates concerns from other disciplines, such as Registry data and Newly diagnosed.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Tricuspid annular displacement predicts survival in pulmonary hypertension.
Paul R. Forfia;Micah R. Fisher;Stephen C. Mathai;Traci Housten-Harris.
American Journal of Respiratory and Critical Care Medicine (2006)
Accuracy of Doppler echocardiography in the hemodynamic assessment of pulmonary hypertension.
Micah R. Fisher;Paul R. Forfia;Paul R. Forfia;Elzbieta Chamera;Traci Housten-Harris.
American Journal of Respiratory and Critical Care Medicine (2009)
Endothelial Dysfunction in Pulmonary Hypertension
Rohit Budhiraja;Rubin M. Tuder;Paul M. Hassoun.
Inflammation, growth factors, and pulmonary vascular remodeling.
Paul M. Hassoun;Luc Mouthon;Joan A. Barberà;Saadia Eddahibi.
Journal of the American College of Cardiology (2009)
Protective effects of sphingosine 1-phosphate in murine endotoxin-induced inflammatory lung injury.
Xinqi Peng;Paul M. Hassoun;Saad Sammani;Bryan J. McVerry.
American Journal of Respiratory and Critical Care Medicine (2004)
Imatinib Mesylate as Add-On Therapy for Pulmonary Arterial Hypertension: Results of the Randomized IMPRES Study
Marius M. Hoeper;Robyn J. Barst;Robert C. Bourge;Jeremy Feldman.
Diagnosis, Assessment, and Treatment of Non-Pulmonary Arterial Hypertension Pulmonary Hypertension
Marius M. Hoeper;Joan Albert Barberà;Richard N. Channick;Paul M. Hassoun.
Journal of the American College of Cardiology (2009)
Comprehensive Invasive and Noninvasive Approach to the Right Ventricle–Pulmonary Circulation Unit State of the Art and Clinical and Research Implications
Hunter C. Champion;Evangelos D. Michelakis;Evangelos D. Michelakis;Paul M. Hassoun.
Characterization of Connective Tissue Disease-Associated Pulmonary Arterial Hypertension From REVEAL: Identifying Systemic Sclerosis as a Unique Phenotype
Lorinda Chung;Lorinda Chung;Juliana Liu;Lori Parsons;Paul M. Hassoun.
Clinical differences between idiopathic and scleroderma-related pulmonary hypertension
Micah R. Fisher;Stephen C. Mathai;Hunter C. Champion;Reda E. Girgis.
Arthritis & Rheumatism (2006)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: